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Objectives: Early treatment of HIV-infected children and adults is important for optimal 
immune reconstitution. Infants’ immune systems are more plastic and dynamic than older 
children’s or adults’, and deserve particular attention. This study aimed to understand 
the response of the HIV-infected infant immune system to early antiretroviral therapy 
(ART) and planned ART interruption and restart.
Methods: Data from HIV-infected children enrolled the CHER trial, starting ART aged 
between 6 and 12 weeks, were used to explore the effect of ART on immune reconsti-
tution. We used linear and non-linear regression and mixed-effects models to describe 
children’s CD4 trajectories and to identify predictors of CD4 count during early and 
interrupted ART.
results: Early treatment arrested the decline in CD4 count but did not fully restore it to 
the levels observed in HIV-uninfected children. Treatment interruption at 40 or 96 weeks 
resulted in a rapid decline in CD4 T-cells, which on retreatment returned to levels 
observed before interruption. Naïve CD4 T-cell count was an important determinant of 
overall CD4 levels. A strong correlation was observed between thymic output and the 
stable CD4 count both before and after treatment interruption.
conclusion: Early identification and treatment of HIV-infected infants is important to sta-
bilize CD4 counts at the highest levels possible. Once stabilized, children’s CD4 counts 
appear resilient, with good potential for recovery following treatment interruption. The 
naïve T-cell pool and thymic production of naive cells are key determinants of children’s 
CD4 levels.
Keywords: hiV, children, antiretroviral therapy, planned treatment interruption, cD4 T cells, cD4 count, thymus
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inTrODUcTiOn
In 2014, 2.6 million children were living with HIV worldwide, and 
under-15s experienced 220,000 new infections, and 150,000 AIDS-
related deaths (1). Despite efforts to extend programs to prevent 
vertical transmission, only 77% of HIV-infected pregnant women 
in 21 priority countries received antiretroviral therapy (ART) (2). 
For some years to come, the optimal management of perinatally 
acquired HIV infection is likely to remain an important issue.
The Children with HIV Early Antiretroviral Therapy (CHER) 
trial (3) provided compelling evidence for early ART initiation 
in perinatally infected infants. Infants enrolled either received 
immediate, time-limited ART followed by planned interrup-
tion, or deferred treatment until meeting predefined clinical 
and immunological criteria (4). Those randomized to deferred 
treatment experienced rapid disease progression and increased 
mortality compared to children treated immediately. In response, 
WHO guidelines changed to recommend universal treatment for 
all children under 1 year of age (4, 5).
Several studies have described CD4 dynamics in older children 
and adults starting, interrupting, and restarting ART. Higher CD4 
counts are achieved in the long term if children start therapy at 
younger ages or with higher pre-ART CD4 counts (6, 7). Children 
restarting ART after planned treatment interruption can recover 
CD4 levels similar to those on continuous ART (8). In adults, the 
effects of interruption are very different: CD4 counts on restarted 
therapy following relatively long interruptions remain lower than 
if on continuous treatment (9, 10). The reasons for the differences 
between children and adults are unclear, but one contributing 
factor may be the much higher thymic export of naïve T-cells in 
children than in adults (11). Thymic activity is decreased in chil-
dren with HIV infection but restored to normal levels in response 
to treatment (12) and may play a role in T-cell reconstitution.
It is also known that there is significant immunological 
variation between individuals, which is influenced by age, sex, 
genetics, antigenic exposure, and other environmental factors 
(13). CD4 counts in healthy children vary with age, and there 
is also significant variation between different children of the 
same age (14, 15). When HIV-infected children start ART, they 
show a range of CD4 responses that were associated with age, 
pre-ART CD4 levels and virological response to treatment (7). In 
any analysis of CD4 response to ART, it is important to consider 
interindividual differences and their potential causes.
We investigated patterns of T-cell homeostasis and reconstitu-
tion in infants interrupting ART during the CHER trial. We show 
that early ART stabilized CD4 levels, but did not increase counts to 
those seen in uninfected children. Following treatment interrup-
tion, ART restored CD4 counts to at least pre-interruption levels. 
Thymic output was a key determinant of both pre- and post-ART 
CD4 counts. This information contributes to our understanding 
of T-cell homeostasis in healthy and HIV-infected children.
MaTerials anD MeThODs
The cher Trial
Children with HIV early antiretroviral therapy was a two-center 
randomized clinical trial comparing three treatment strategies 
in infants with perinatally acquired HIV-1 infection diagnosed 
between 6 and 12 weeks of age. Infants were recruited through 
PMTCT programs at the Perinatal HIV Research Unit (PHRU) 
in Soweto, Johannesburg and the Children’s Infectious Diseases 
Clinical Research Unit (KIDCRU) in Tygerburg, Cape Town, 
South Africa. Research ethics committees in South Africa and 
the USA approved the trial. Parents or guardians gave written 
consent for screening and enrollment. Children with CD4% 
≥25% at screening were eligible for randomization to one of 
three ART regimens: deferred treatment (ART-Def), and either 
40 weeks (ART-40W) or 96 weeks (ART-96W) of early treatment 
starting between 6 and 12 weeks. The ART-40W and ART-96W 
groups then interrupted treatment, except in a few cases of treat-
ment failure where a trial endpoint was met (Figure 1). Children 
were monitored during treatment interruption, and continuous 
therapy was re-initiated according to predefined clinical, immu-
nological, or virological criteria (3). Children were seen every 
4 weeks from enrollment until week 24, eight-weekly to week 48 
and 12-weekly thereafter. In this analysis, we consider the CD4 
counts collected at clinic visits. The protocol and primary results 
are reported fully elsewhere (3).
To be included in our analysis, children had to have CD4 meas-
urements made while on early and/or continuous ART. Children 
who did not start early ART were, therefore, excluded from our 
analysis of early ART trajectories. The analysis of continuous ART 
trajectories excluded children who did not interrupt ART, who 
did not (re-)start continuous ART during the follow-up period, 
or who (re-)started but had no continuous-ART CD4 measure-
ments available (Figure 1).
In a substudy of CHER, naive and memory T-cell levels were 
measured retrospectively by flow cytometry using cryopreserved 
peripheral blood mononuclear cells (PBMCs). We analyzed at 
most one timepoint per participant during early therapy (chosen 
at random if more than one early-therapy timepoint per child 
was available). We also considered the first available timepoint 
on continuous therapy, included only if measured at <20 weeks 
after restarting ART, and the last available timepoint on con-
tinuous therapy, included only if measured >100  weeks after 
restarting ART.
The original CHER study received ethical approval from 
the Health Research Ethics Committee of the University of 
Stellenbosch with reference number M04/07/033A and from 
the University of the Witwatersrand Human Research Ethics 
Committee under ethics reference number 040703. The sub-
study providing the more detailed immunological data was 
also approved by ethics committees at Stellenbosch University 
(reference number M12/01/005) and the University of the 
Witwatersrand (with the same reference: 040703).
age-correction for cD4 counts
Total naïve and memory CD4 counts vary with age in healthy 
children, changing particularly rapidly during infancy (14). To 
compare CD4s in children of different ages and in the same child 
at different times, z-scores based on reference data from HIV-
uninfected children born to HIV-infected mothers in Europe 
were used (15, 16). (Functions for z-scores based on healthy 
South African children are not currently available.) A z-score of 
FigUre 1 | Enrollment, dropout, and antiretroviral therapy (ART) of children in the children with HIV early antiretroviral therapy trial. LTFU, lost to follow-up.
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0 corresponds to the median CD4 count for a healthy child of the 
same age, a positive value indicates a count above the median and 
a negative value a count below the median. Approximately 95% of 
healthy children have CD4 z-scores between −2 and 2.
Naïve and memory cell counts were expressed as the natural 
logarithm of the ratio of the count to that expected in a healthy 
child of the same age (14). A value less than 0, therefore, repre-
sents a count below average and a value above 0 a level above 
average for a healthy child:
 
Naive CD -for-age
Naive CD  count
Naive CD  count expected 
4
4
4
=
in a healthy child of the same age
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4
4
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=
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It is important to note that neither of the reference datasets 
used for age-adjusted CD4 counts were collected from Black 
African children living in Africa although the reference data 
for CD4 z-scores included a number of Black African children 
living in Europe. Ethnic and/or environmental differences may 
affect total naïve and memory CD4 counts (17, 18). To compare 
reference values between the European children used to calculate 
z-scores and Black African children living in Africa, immu-
nophenotypic data were obtained from the Child Wellness Clinic 
(CWC) for children from birth up to 12 years of age, established 
at a community health clinic in Wesbank, a suburb in the Eastern 
subdistrict of Cape Town. The primary aim of the CWC was to 
acquire HIV-uninfected blood specimens comparable to CHER 
participants in terms of intercurrent infection, nutrition, vaccina-
tion, and socio-economic status to establish hematological and 
immunological reference ranges (19) and measure thymic output 
in healthy children. The z-scores calculated for this population as 
described above were comparable to the European z-scores and 
were also compared with HIV-infected children (see Results).
characterizing cD4 Trajectories
We previously characterized CD4-for-age trajectories in HIV-
infected older children on ART by a combination of non-linear 
mixed-effects modeling and linear regression (7). Here, we used 
the same process to classify trajectories in these younger chil-
dren and infants from the CHER trial restarting ART following 
interruption.
Each child’s CD4 z-scores were fitted to a curve of the form:
 CD4 -score int asy int exp , z ct= − ( ) ( )− × −  (1)
where t represents time since ART initiation (Figure 2A). This 
“asymptotic” pattern of recovery assumes an initially low CD4 
z-score (the intercept, int) which increases quickly at first, slowing 
down with time to approach a stable long-term level (the asymp-
tote, asy). The parameter c characterizes the rate of this recovery. 
The aim of this initial model was to separate children with a clear 
asymptotic pattern of recovery from those with qualitatively dif-
ferent recovery profiles. If the CD4 z-score trajectories did not fit 
FigUre 2 | Schematic illustration of the model for CD4 z-score trajectories. 
(a) The “asymptotic” model of CD4 z-score recovery following antiretroviral 
therapy (ART) initiation or restart. (B) A model of CD4 z-score in a child 
interrupting and restarting ART, including an early stable CD4 z-score, a fall in 
z-score during interruption (not modeled) and an asymptotic recovery on ART 
restart.
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the asymptotic pattern (model non-convergence), linear regres-
sion was used to identify children in whom there was evidence 
that CD4 z-score was increasing or decreasing (p < 0.05 for the 
null hypothesis of a slope not significantly different from 0), and 
children in whom there was no evidence of any change (p > 0.05).
Preliminary investigations suggested that the asymptotic model 
was not appropriate for most children during early therapy. CD4 
z-score trajectories during early therapy were, therefore, classified 
using only linear regression, as having increasing or decreasing 
CD4 z-score (p < 0.05) or no evidence of any trend (p > 0.05).
Mixed-effects Modeling of longitudinal 
cD4 Data
To investigate the relationship between CD4 z-scores on early 
therapy, at ART restart and in the long term, a non-linear mixed-
effects model incorporating the asymptotic response function 
(Eq.  1) was used. CD4 z-score on early therapy is assumed 
constant, as observed in the majority of children. After ART 
interruption, the CD4 z-score falls according to a trajectory not 
specified in the model, and data collected during interruption 
was, therefore, excluded from the model fitting. The model 
included four parameters: the stable z-score level while on early 
ART, the z-score when ART was restarted following interruption, 
the difference between the stable level on early therapy and on 
long-term restarted therapy, and the time constant characterizing 
the speed of the asymptotic increase (Figure 2B). This param-
eterization allows formal statistical testing of the hypothesis that 
the difference between stable CD4 z-scores on early and long-
term therapy is not significantly different from 0.
In mixed-effects models, parameter values are inferred for the 
population on average (fixed effects) and can also be allowed to 
vary between individual children (random effects). In the model 
used here, the four parameters were all allowed to vary between 
children, with non-zero covariance between parameters (i.e., cor-
relation between parameters was allowed). An additional fixed 
effect was introduced when ART was restarted after treatment 
interruption to allow a systematic difference between the first 
CD4 z-score observed after therapy restarted and the intercept 
of the asymptotic curve, as we found that this significantly 
improved the fit to the data (objective function value (OFV), 
−2 × log-likelihood, reduced by 17 U). This model was compared 
to one where the steady-state CD4 z-score on initial treatment 
changed continuously with time since enrollment (rather than 
undergoing a “step” during interruption) but although the objec-
tive function decreased by 8 U, the rate of change was estimated 
as (−1.47 ± 0.87) × 10−4 z-score units week−1 (value, SE) and there 
was, thus, no significant evidence of a slope significantly different 
from 0.
Mixed-effects models also allow predictive effects of child-
specific covariates on the model parameters to be investigated. 
We investigated the effects of study site, sex, weight at birth, age 
and weight at enrollment (original ART initiation), CDC disease 
stage at enrollment and duration of early therapy (trial rand-
omization) on all four parameters of the model, and the effects 
of reason for restarting ART, age at restarting and interruption 
length on CD4 z-score at ART re-initiation, CD4 z-score in the 
long term, and rate of CD4 recovery. We did not use CD4 z-score 
at enrollment as an additional factor, because it was stable and, 
therefore, its influence on long-term CD4 z-scores was already 
included through the random effects. We used forward selection 
for building the covariate models, comparing the change in OFV 
to a χ2 distribution and including new models with p-values for 
the new covariate less than 0.1. This was followed by a backwards-
elimination phase with a threshold p-value of 0.05. (We report 
p-values for the null hypothesis of no significant difference in the 
fit in this backward-elimination process.) Finally, we checked the 
effect on OFV of adding further covariates to our final model.
The mixed-effects framework we used for analysis has several 
advantages. First, it provides a statistically rigorous approach 
for analyzing longitudinal data, allowing the full power of the 
whole dataset to inform the results. More traditional methods 
are usually limited to simpler analyses on a subset of the data: 
for example, comparing pairs of timepoints. Second, mixed-
effects models allow very explicitly for interindividual variability. 
Immunological variation between individuals is significant and 
is of particular interest in this analysis of between-child differ-
ences in CD4 response and their possible causes. Mixed-effects 
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Frontiers in Immunology | www.frontiersin.org September 2017 | Volume 8 | Article 1162
modeling provides a tool to investigate predictive effects of 
measured covariates on the CD4 response. Finally, non-linear 
mixed-effects models can account for complex trial protocols 
like CHER’s because they are very flexible in the form of the CD4 
response that can be proposed.
Thymic Output
Thymic output was estimated by combining measurements of T cell 
receptor excision circles (TRECs) from purified naïve CD4 
T-cells with Ki67 labeling to calculate the rate of peripheral naïve 
T-cell production as described previously (11). Naïve CD4 T cells 
were identified by staining for CD4 + CD45RA+ lymphocytes, 
and dividing naïve CD4 T cells were determined using the prolif-
eration marker Ki67. Ki67 is only expressed in proliferating cells 
in late stage GI then is subsequently rapidly degraded and can, 
therefore, be used to represent the population of dividing cells.
The equation for thymic export (θ) in terms of total naïve cell 
numbers, naïve cell TREC content and Ki67 expression is given as:
 
θ
τ
τ
t y N
c
( ) = × ×
−( )∆
,
 
where y is the fraction of naïve CD4 T  cells expressing Ki67, 
Δ is the duration of Ki67 expression [set to 0.52 (11)], τ is the 
TREC content of the peripheral naïve CD4 T cell population, c is 
a constant representing the average TREC content of thymocytes 
entering the peripheral naïve population [set to 0.6 (11)], and N is 
the total size of the naïve CD4 T cell pool estimated by multiply-
ing the number of naïve CD4 T cells per microliter of blood by 
the total volume of blood [0.97 × Log(body weight in kg) + 4.93] 
then dividing this figure by 0.02 as blood lymphocytes account for 
approximately 2% of the body’s total lymphocyte population (11).
software
Linear and non-linear regression was carried out in the R statisti-
cal environment (20). For mixed-effects modeling, we used NON-
MEM version 7.3 (21) with the SAEM algorithm for parameter 
inference, followed by importance sampling to estimate SEs on 
parameter values and obtain the OFV. The NONMEM control 
file for the final model is available on request. Perl-speaks-NON-
MEM (PsN) was used for covariate analysis (22).
resUlTs
Four hundred eleven children were enrolled in the CHER trial. 
Their baseline characteristics by randomization arm are provided 
in Table S1 in Supplementary Material. Figure 1 shows the num-
bers of children progressed to each trial stage: starting, interrupt-
ing, and restarting therapy according to the protocol.
cD4-for-age in children on early arT is 
stable or regresses to a Mean 
significantly below that of Uninfected 
children
Of 284 children starting early ART (141 ART-40W; 143 ART-
96W), 10 (4%) had ≤2 CD4 measurements available following 
ART initiation. CD4 z-scores in the remaining 274 are shown in 
Figure 3A. Of these, 215 (78%) showed no evidence of a trend in 
CD4 z-score with time on ART (p > 0.05). There was a downward 
trend despite ART in 27 (10%) and an increasing trend in 32 (12%). 
Children with increasing CD4 z-score had the lowest CD4 counts 
and z-scores at ART initiation, while children with decreasing 
scores had the highest (both p < 0.0001). Unsurprisingly, children 
with increasing CD4 z-scores also had more advanced disease, 
while children with decreasing CD4 z-scores were more likely 
to be asymptomatic (p  =  0.030) (Table S2 in Supplementary 
Material). These results suggest a regression-to-the-mean phe-
nomenon on early ART, where z-scores in children with more 
advanced disease improve and in children with milder disease 
decline toward the population average.
Figure 3C shows mean CD4 z-scores on early ART. Although 
there is some fluctuation, it confirms that the CD4 z-score 
was stable during early therapy. Importantly, Figure  3C also 
shows that even though these children started ART early, aged 
between 6 and 12  weeks, the stable average CD4 z-score was 
significantly below 0. For comparison, CD4 z-scores in >400 
HIV-uninfected South African children from the CWC (19) had 
mean ± SEM −0.06 ± 0.05, significantly higher than the HIV-
infected children on early ART. When early ART was initiated, 
CD4 z-scores were comparable to infants randomized to defer 
treatment (−0.82  ±  0.07 versus −0.64  ±  0.09). By 12  weeks, 
however, z-scores for the ART-deferred cohort had declined to 
−1.50  ±  0.13 but for the children on ART remained stable at 
around −0.8 (Figures 3A,C). These results show that early ART 
over 40 or 96 weeks arrests the decline in CD4 T-cells but does not 
restore CD4 levels to those in uninfected children.
cD4 T-cell reconstitution in children 
restarting arT after Planned Treatment 
interruption
Children in ART-40W or ART-96W restarted ART after inter-
ruption, according to predefined criteria (see Materials and 
Methods). Figures 3B,D shows CD4 z-scores for children restart-
ing ART following planned interruptions. One hundred seventy-
two children restarted treatment, of whom seven had no CD4 
count available after restarting. The median (IQR) interruption 
length in the 165 children with at least one CD4 count on con-
tinuous therapy was 26 (11–48) weeks. Nineteen of the 165 had 
interruption length 0 because they were already eligible for ART 
restart at the interruption date. In 155 of the 165 children who 
restarted treatment, we identified four distinct response groups 
similar to those seen in older children (Table S3 in Supplementary 
Material) (7); CD4 response could not be classified in the remain-
ing 10, who had fewer than three CD4 measurements after restart. 
In 94 children (61%), CD4 z-score increased and then plateaued 
(“asymptotic reconstitution”; Figure  4A). These children had 
lower pre-ART-restart CD4 counts (p  =  0.0005) and z-scores 
(p = 0.0002) than the remaining study population but there was 
no evidence of differences in other characteristics (all p > 0.3). 
In 47 children, CD4 z-scores were stable (p > 0.05; Figure 4B), but 
at a lower average level than the asymptotic group. These children 
had higher CD4 counts (p = 0.0027) and z-scores (p = 0.0011) at 
FigUre 3 | CD4 T-cell dynamics in children on early antiretroviral therapy (ART) and on continuous ART restarted after treatment interruption. (a) Individual CD4 
z-score trajectories for children on early ART for 96 weeks (ART-96W) and 40 weeks (ART-40W). (B) Individual CD4 z-score trajectories on continuous ART restarted 
after treatment interruption. (c) Means and SEs in the mean (±SEM) of combined ART-96W and ART-40W CD4 z-scores for each sampling time on early treatment. 
The continuous straight line indicates the population-average model fit for the ART-96W and 40 W samples, showing stability of the z-scores over time. The z-scores 
in these early-treated children are significantly lower than the mean (±SEM) of the HIV-uninfected Child Wellness Clinic (CWC) cohort. (D) Means and SEM of CD4 
z-scores for each sampling time after ART restart, with the population-average model fit. The discrepancy between the beginning of the curve and the first point is 
likely to be due to redistribution of memory T-cells in response to ART restart and viral suppression.
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ART re-initiation than the asymptotic group. CD4 z-scores in 11 
children increased to higher levels than those in the other groups, 
but did not reached a plateau during observation (Figure 4C). 
These children also had higher CD4 z-scores at ART restart than 
the asymptotic group (p = 0.0074), and there was some evidence 
of higher CD4 counts (p = 0.012). CD4 z-scores fell with time on 
ART in only three children (Figure 4D).
Understanding the impact of Planned arT 
interruption on long-Term cD4 levels 
when Therapy is restarted
Non-linear mixed-effects modeling was used to identify factors 
determining the effect of treatment interruption on T-cell recon-
stitution following ART interruption and better understand its 
long-term impact. The results are reported in terms of an “aver-
age” child for this study: belonging to the largest groups (female, 
enrolled at PHRU, randomized to ART-40W and restarting ART 
for clinical reasons) with median enrollment age 8 weeks, restart 
age 103 weeks, and interruption length 22 weeks. Such an “aver-
age” child had stable CD4 z-score on early therapy at - 0.79 ± 0.05 
(estimate  ±  SE), corresponding to the 21st centile in healthy 
children. Following interruption, therapy was restarted in this 
“average” child at a z-score of –1.55 ± 0.16, corresponding to the 
sixth centile in healthy children. The CD4 z-score increased with 
rate constant 0.016 ± 0.006 weeks-1 so that the time to achieve 
half of the long-term increase (ln2/rate constant) was ~43 weeks. 
The long-term CD4 z-score (asymptote) on continuous restarted 
therapy was 0.13 ± 0.13 units higher than the stable level on early 
(pre-interruption) therapy. There was, therefore, no evidence of 
FigUre 4 | CD4 recovery after restarting continuous antiretroviral therapy (ART) following treatment interruption in ART-40W and ART-96W. (a) The majority of 
children (94, 61%) showed an asymptotic response. (B) 47 children had stable average z-score after an initial increase, possibly due to CD4 T-cell redistribution.  
The stable z-score at ART restart in these children was significantly lower than that for the asymptotic group. (c) 11 children showed continual increase in z-scores 
ending up above the plateau reached in the asymptotic group. (D) Decreasing z-scores were seen in three children. All error bars give the SE of the mean.  
The gray line in panels (B–D) reproduces the mean z-score shown in panel (a).
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any decrease in long-term CD4 z-score on long-term ART as a 
result of treatment interruption, relative to the stable z-score on 
early treatment.
The analysis identifies factors influencing CD4 z-scores for 
individual children on early treatment and restarting treatment 
after planned ART interruption. On early ART, children who 
were older at ART initiation had lower but stable CD4 z-scores 
(−0.087 ± 0.032 U lower, per week older at enrollment; p = 0.016). 
After treatment interruption, children restarted ART with higher 
CD4 z-scores if they were male (0.252  ±  0.151  U higher; 
p =  0.036), were older when ART was restarted (0.243 ±  0.147   
U higher; p = 0.032) or, unsurprisingly, if they restarted therapy 
for clinical (0.331 ± 0.172 U higher) or unspecified (0.666 ± 0.280  
U higher) as opposed to immunological reasons (p = 0.018). CD4 
z-score at restart was lower if ART had been interrupted for longer 
[(−9.98 ± 2.99) × 10−3 U lower per week of interruption; p = 0.0004]. 
The increase in CD4 count was exp(0.0140) =  1.01 times faster 
per week of treatment interruption. Table S4 in Supplementary 
Material summarizes these results. Notably, there was no evidence 
that either duration of early therapy (96 versus 40 weeks) or length 
of interruption predicts CD4 levels on long-term, restarted ART, 
once other covariates have been taken into account.
Significant correlations were found between children’s CD4 
z-scores on early therapy, at ART restart after treatment inter-
ruption and long-term stable levels (Table S5 in Supplementary 
Material). This suggests that children have an individual CD4 “set 
point” established on early therapy, to which they return when 
therapy is restarted after interruption.
TaBle 1 | Spearman’s correlations (ρ) and p-values between z-scores and naïve and memory cells measured as log ratios to normal age-matched children.
naïve and memory cD4-for-age ratio  
to uninfected children
correlation with cD4 z-score obtained  
from the model
On early treatment at arT restart in the long term
Early treatment Naïve ρ = 0.61, p < 10−4 ρ = 0.51, p < 10−4 ρ = 0.48, p < 10−4
Memory ρ = 0.40, p = 0.0009 ρ = 0.25, p = 0.048 ρ = 0.31, p = 0.012
Treatment restart Naive ρ = 0.43, p = 0.014 ρ = 0.76, p < 10−4 ρ = 0.67, p < 10−4
Memory ρ = 0.17, p = 0.36 ρ = 0.51, p = 0.0030 ρ = 0.51, p = 0.0033
Long-term treatment Naïve ρ = 0.69, p < 10−4 ρ = 0.44, p = 0.003 ρ = 0.83, p < 10−4
Memory ρ = 0.19, p = 0.23 ρ = 0.45, p = 0.0025 ρ = 0.50, p = 0.0006
Bold font is used to highlight p-values below 0.01. Naïve and memory cell counts were analyzed using at most one timepoint per participant during early therapy (chosen at random 
if more than one early-therapy timepoint per child was available); the first available timepoint on continuous therapy, included only if measured at <20 weeks after restarting ART; and 
the last available timepoint on continuous therapy, included only if measured >100 weeks after restarting ART.
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naïve cD4 cells are a Key Determinant  
of Total cD4 reconstitution
Age-adjusted naïve and memory cell counts and thymic output 
were available at three stages: on early ART (66 children), soon 
after restart (32 children), and in the long term (44 children).
The early stable CD4 z-score prior to treatment interruption 
was positively correlated with the naïve CD4-for-age during early 
treatment and after long-term therapy, and with the memory 
CD4-for-age on early therapy but not the memory CD4-for-age 
on long-term therapy (Table 1). Thus, early stable CD4 z-score 
level prior to treatment interruption appears to be related to naïve 
CD4-for-age throughout treatment, but not to predict memory 
CD4-for-age on long-term therapy.
The CD4 z-score at ART restart following interruption was 
correlated with naïve CD4-for-age before interruption, on restart 
and in the long term (Table 1). Furthermore, it correlated with 
memory CD4-for-age at ART restart and long term but not on 
early therapy. This could be due to changes in memory CD4-for-
age related to viral exposure during treatment interruption. This 
concept is reinforced as the long-term CD4 z-score was also cor-
related with naïve CD4-for-age on early therapy, at restart and long 
term, but with memory CD4-for-age only at restart and long term.
Thymic Output Drives cD4 reconstitution
There is a significant positive correlation between thymic export 
and z-score on early ART, and also the long-term stable z-score 
on ART after treatment interruption (Figures  5A,B). Thymic 
export measured after treatment restart was also correlated 
with long-term stable CD4 z-score (Figure  5C). These results 
indicate that the levels of naïve CD4 cells that strongly influence 
CD4 count before and after interrupting ART arise from thymic 
output rather than peripheral cell division and that effective T-cell 
reconstitution depends significantly on the export rate of naïve 
T-cells from the thymus.
DiscUssiOn
CD4 counts from CHER provide a unique opportunity to 
explore the dynamics of CD4 reconstitution in HIV-infected 
infants. During early ART, children’s CD4 z-scores were stable 
but remained significantly below those of uninfected children. 
Even when ART is started within the first 12 weeks of life it only 
maintains CD4 levels, rather than reinstating healthy counts.
Most children in the early treatment arms stopped ART at 
either 40 or 96  weeks. When ART was restarted, according to 
predefined criteria, a range of CD4 recovery profiles similar 
to those seen in other studies of older children were observed 
(7). The largest group experienced an asymptotic rise in CD4 
z-score followed by a plateau. A smaller group of children saw 
lesser initial increases but stabilized soon after ART reintroduc-
tion; these children’s CD4 z-scores had remained relatively high 
during treatment interruption but remained below the average 
long-term level in the asymptotic group. In the small group of 
children in whom CD4 counts increased continuously until the 
end of the trial, long-term CD4 levels were higher than in the 
asymptotic group. Only three children had falling CD4 levels 
following treatment restart.
We showed that long-term CD4-for-age recovery was equiva-
lent to children’s pre-interruption steady state. Although current 
guidelines do not recommend ART interruption, situations 
inevitably arise where individual children interrupt because 
of poor tolerance, family choice, or for logistical reasons. Our 
analyses suggest that such interruptions in young children who 
started ART with relatively high CD4s, if planned, monitored and 
controlled, may not harm long-term CD4 reconstitution. This 
may provide reassurance in  situations where interruptions are 
unavoidable. The observation is consistent with previous work, 
suggesting that children starting ART for the first time at young 
ages have good potential for long-term CD4 recovery (6), for a 
combination of possible reasons including the preservation of 
both thymic activity (11, 23) and the machinery of T-cell homeo-
stasis in the lymph nodes (24). It is also consistent with data 
suggesting planned treatment interruptions in older children 
do not damage CD4 counts in the long term (8). This remark-
able capacity for young children to reconstitute T-cells contrasts 
with adults in whom treatment interruption is associated with 
impaired reconstitution (9, 10).
The level of children’s early stable CD4-for-age was predicted 
by age at first ART initiation. Once started, ART stabilized CD4-
for-age for the long term and neither the length of early treatment 
(96 versus 40  weeks), nor the period of interruption appeared 
to affect long-term levels. This may be a result of the restricted 
FigUre 5 | Continued  
Correlation between thymic output and CD4 z-score. (a) Thymic output 
measured on early antiretroviral therapy (ART) is significantly correlated with 
early stable CD4 z-score (ρ = 0.39, p = 0.0002). (B) Thymic output on early 
ART is significantly correlated with long-term stable z-score after restarting 
ART (ρ = 0.40, p = 0.0002). (c) Correlation between thymic output 
measured on ART restart and long-term stable z-score (ρ = 0.32, p = 0.006). 
Correlations determined by two-tailed tests based on the Spearman 
correlation coefficient ρ.
FigUre 5 | Continued
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range of interruption lengths in our study—CD4 trajectories 
could only be studied in those children who restarted during 
the 5–6 years of trial data available—but could also suggest that 
early therapy protects the immune system, especially the thymus, 
at a crucial developmental phase (12). The correlation between 
thymic output and CD4 z-scores during early treatment and after 
interruption supports this concept, reinforcing the importance 
of early diagnosis and treatment to preserve CD4 counts and 
provide a degree of immunological resilience should treatment 
be interrupted in the future.
A striking finding was the strong correlation between CD4 
levels on early therapy, at ART re-initiation and long term. 
It seems that children have a CD4 “set point,” established 
on early ART, to which they return on long-term treatment, 
even post-interruption. This is consistent with the correlation 
between CD4 z-scores and both thymic output and naïve 
T-cells and might suggest that the preserved CD4 set-point is 
dependent on thymic output and naïve CD4 T-cell dynamics. 
This is in contrast to adults, in whom memory T-cell dynam-
ics play a greater role in reconstitution (25). Despite the high 
thymic output in young children, most infants treated with 
early ART achieved maximal CD4 levels significantly below the 
uninfected children in the CWC cohort. It appears that a CD4 
“ceiling” is established in utero or in early childhood, which is 
likely to remain for life. The implications of such a CD4 “ceil-
ing” for children as they age, and particularly in adulthood, are 
unclear. It does, however, suggest that immunotherapy with, 
for example, interleukin-7 (26) might be considered to enhance 
CD4 levels in children.
The main limitation of the study is that we could only exam-
ine CD4 trajectories on restarted ART in those children who 
restarted therapy during the 5–6  years of data available, and 
not in the 19% of ART-40W and 32% of ART-96W children 
remaining off ART at the end of the trial. Data from long-term 
follow-up of these children, or cohort studies, could add to our 
conclusions in the future by providing outcomes in these children 
with longer interruptions. Another limitation is the functions 
used for age-adjustment of total naïve and memory CD4 counts, 
which are based on reference data from European children. 
No age-standardization functions for these counts in South 
African children currently exist, and formulating them would 
provide a useful clinical and research tool. Finally, CD4 count 
is only one aspect of the all-round immunological health for 
which effective HIV management aims. Further monitoring 
and research into the wider immunological effects of planned 
treatment interruptions—for example, the possibility of immune 
activation and associated risks—is important.
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This study demonstrates that early identification and treatment 
of HIV-infected infants is not only important for clinical reasons, 
but optimizes the CD4 levels achieved with ART in the long term, 
albeit below levels in uninfected children. Once stabilized, CD4 
counts appear resilient, with good potential for recovery follow-
ing treatment interruption. Our analysis of naïve and memory 
T-cell subsets and thymic output indicates that the thymus is key 
to maintaining the naïve pool and determining children’s CD4 
levels. This is a major difference between children and adults, and 
a greater understanding of T-cell dynamics in young children 
could provide valuable insights into approaches for optimizing 
immune reconstitution for vertically infected children presenting 
at older ages (27). The WHO has recently changed its policy, and 
now recommends universal therapy regardless of CD4 count (28). 
Long-term studies are required to ascertain how the reduced CD4 
ceiling observed for the first time here will influence the health of 
these children in adulthood.
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